#United States #California #Levi & Korsinsky #federal securities #Vistagen

Vistagen Therapeutics Class Action Lawsuit

Levi & Korsinsky, LLP has announced a securities class action against Vistagen Therapeutics, Inc. (NASDAQ: VTGN), a notable event under U.S. federal securities laws. This legal action aims to address significant concerns related to the company’s disclosures and potential misleading statements that allegedly affected investors during a specified time frame.

Overview of the Allegations

The lawsuit focuses on Vistagen's activities from April 1, 2024, to December 16, 2025. Investors who purchased stock within this period and incurred financial losses are encouraged to review their status, as they may be eligible to join the class action. The main complaint was filed in the United States District Court, Northern District of California, under case number 326-cv-00427.

The legal claims asserted in this case rely on several provisions of the Securities Exchange Act of 1934, particularly Section 10(b) and Section 20(a). Section 10(b) and Rule 10b-5 prohibit deceptive practices when buying or selling securities. This includes making materially false statements or omissions that could mislead investors. Section 20(a) concerns the liability of individuals who had control over persons responsible for the misleading actions.

Class Definition and Exclusions

The defined class includes all individuals and entities that purchased or otherwise acquired common stock of Vistagen during the designated period. Upon exposure of the misleading disclosures, affected individuals may have sustained damages, which are central to the claims being presented.

Notably, certain groups are explicitly excluded from this class. This includes defendants, members of the company’s management and their immediate families, as well as their legal representatives.

Legal Procedures Under PSLRA

As per the Private Securities Litigation Reform Act of 1995, members of the proposed class have an opportunity to serve as lead plaintiff. They can file a motion to this effect with the court until March 16, 2026. The lead plaintiff will have the authority to represent the class through the litigation process, influencing its direction and decisions.

Importantly, the ability of individual members to recover damages won’t be compromised by their choice to assume the role of lead plaintiff.

Actionable Steps for Investors

Investors who believe they have been affected by Vistagen's alleged misleading practices can learn more about the lawsuit or get in touch with legal representatives. Interested parties may contact Joseph E. Levi, Esq. via email or phone for further information on their potential eligibility and the class action details.

About Levi & Korsinsky, LLP

Levi & Korsinsky has a rich history in shareholder advocacy, successfully securing hundreds of millions of dollars for aggrieved investors over two decades. With expertise in complex securities litigation, the firm boasts a dedicated team of more than 70 professionals. Their commitment to investor protection has earned them recognition as a leading firm in the field, consistently ranking high in ISS Securities Class Action Services assessments.

In this dynamic context, the ongoing developments in the Vistagen Therapeutics case are being closely monitored by investors and legal professionals alike, highlighting the importance of transparency and responsibility among public companies.